Buisson A, Nachury M, Fumery M. Checking the absence of inflammatory activity with an objective marker, a key point to succeed the switch from intravenous to subcutaneous infliximab in inflammatory bowel disease. Clin Gastroenterol Hepatol 2022 Nov 16:S1542-3565(22)01084.
PMID: 36402373